Preventive Cognitive Therapy versus Treatment as Usual in preventing recurrence of depression: protocol of a multi-centered randomized controlled trial

BMC Psychiatry

Jack JM Dekker¹  Judith E Bosmans²  Martijn J Kikkert¹  Claudi LH Bockting³  Margo de Jonge¹ 

[1] Department of research Arkin, Klaprozenweg 111, Amsterdam, 1033 NN, The Netherlands;Department of Health Sciences and the EMGO Institute for Health and Care Research, Faculty of Earth and Life Sciences, Vrije Universiteit, De Boelelaan 1085, Amsterdam, 1081 HV, The Netherlands;Department of Clinical Psychology, Utrecht University, Heidelberglaan 1, Utrecht, 3584 CS, The Netherlands

关键词: Prevention;    Cognitive Therapy;    Recurrence;    Relapse;    Depression;   

Others  :  1217929
DOI  :  10.1186/s12888-015-0508-8

 received in 2014-12-18, accepted in 2015-05-26,  发布年份 2015

【 摘 要 】

Background

Major depressive disorder (MDD) is projected to rank second on a list of 15 major diseases in terms of burden in 2030. The contribution of MDD to disability and health care costs is largely due to its highly recurrent nature. Therefore, part of the efforts to reduce the disabling effects of depression should focus on preventing recurrence, especially in patients at high risk of recurrence. The best established effective psychological intervention is cognitive therapy, with indications for prophylactic effects after remission.

Methods/Design

In this randomized controlled trial (cost-) effectiveness of Preventive Cognitive Therapy (PCT) after response to Acute Cognitive Therapy (A-CT) will be evaluated in comparison with Treatment As Usual (TAU). Remitted patients that responded to A-CT treatment with at least two previous depressive episodes will be recruited. Randomization will be stratified for number of previous episodes. Follow-ups are at 3, 6, 12 and 15 months. The primary outcome measure will be the time to relapse or recurrence of depression meeting DSM-IV criteria for a major depressive episode on the Structured Clinical Interview for DSM-VI Axis I Disorders (SCID-I). Costs will be measured from a societal perspective.

Discussion

This study is the first to examine the addition of PCT to TAU, compared to TAU alone in patients that recovered from depressive disorder with A-CT. Alongside this effect study a cost effectiveness analysis will be conducted. Furthermore, the study explores potential moderators to examine what works for whom.

Trial registration

Netherlands Trial Register (NTR): 2599, date of registration: 11-11-2010.

【 授权许可】

   
2015 De Jonge et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al.: Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
• [2]Peen J, Dekker J, Schoevers RA, Have MT, de Graaf R, Beekman AT: Is the prevalence of psychiatric disorders associated with urbanization? Soc Psychiatry Psychiatr Epidemiol 2007, 42:984-989.
• [3]Dekker JJ, Koelen JA, Van HL, Schoevers RA, Peen J, Hendriksen M, et al.: Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord 2008, 109:183-188.
• [4]Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
• [5]Hardeveld F, Spijker J, de Graaf R, Nolen WA, Beekman AT: Recurrence of major depressive disorder and its predictors in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med 2013, 43:39-48.
• [6]Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al.: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000, 157:229-233.
• [7]Bockting CL, Spinhoven P, Wouters LF, Koeter MW, Schene AH: Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study. J Clin Psychiatry 2009, 70:1621-1628.
• [8]Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy’s effects. J Consult Clin Psychol 2007, 75:475-488.
• [9]Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S: Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004, 161:1872-1876.
• [10]Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al.: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998, 50:97-108.
• [11]Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M, Andersson G: Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 2013, 3:e002542.
• [12]Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O’Reardon JP, et al.: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005, 62:417-422.
• [13]Hollon SD: Cognitive and behavior therapy in the treatment and prevention of depression. Depress Anxiety 2011, 28:263-266.
• [14]Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008, 77:17-26.
• [15]Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA: Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004, 60:57-61.
• [16]ten Doesschate MC, Bockting CL, Koeter MW, Schene AH: Predictors of nonadherence to continuation and maintenance antidepressant medication in patients with remitted recurrent depression. J Clin Psychiatry 2009, 70:63-69.
• [17]Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998, 5:293-306.
• [18]Van Schaik DJ, Klijn AF, van Hout HP, van Marwijk HW, Beekman AT, de Haan M, et al.: Patients’ preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2004, 26:184-189.
• [19]Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC: Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001, 58:381-388.
• [20]Jarrett RB, Vittengl JR, Clark LA: How much cognitive therapy, for which patients, will prevent depressive relapse? J Affect Disord 2008, 111:185-192.
• [21]Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, et al.: Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005, 73:647-657.
• [22]Guidi J, Fava GA, Fava M, Papakostas GI: Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med 2011, 41:321-331.
• [23]Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive therapy of depression. Guilford Press, New York; 1979.
• [24]Bockting CLH: Preventieve cognitieve training bij terugkerende depressie. Bohn Stafleu van Loghum, Houten; 2009.
• [25]World Medical Association: WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. 2013.
• [26]Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992, 49:624-629.
• [27]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [28]Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996, 26:477-486.
• [29]Steer RA, Rissmiller DJ, Beck AT: Use of the Beck Depression Inventory-II with depressed geriatric inpatients. Behav Res Ther 2000, 38:311-318.
• [30]Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ: [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd 2005, 149:1574-1578.
• [31]Hakkaart-van Rooijen L, van Straten A, Donker M, Tiemens B. Manual Trimbos/IMTA questionnaire for costs associated with Psychiatric Illness (TIC-P). Edited by Institute for Medical Technology Assessment. 2002. Rotterdam, The Netherlands: Erasmus University Rotterdam.
• [32]Hakkaart-van Roijen L, Tan SS, Bouwmans CAM: Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidzorg. Geactualiseerde versie 2010. [Dutch manual for costing in economic evaluations]. College voor zorgverzekeringen (CVZ), Diemen; 2011.
• [33]Vingerhoets AJJM, van Tilburg MAL: Everyday Problem Checklist (EPCL). Swets & Zeitlinger B.V, Lisse; 1994.
• [34]Akkerhuis GW, Kupka RW, van Groenestijn MAC, Nolen WA: PDQ-4+ Vragenlijst voor persoonlijkheidskenmerken. Swets & Zeitlinger, Lisse; 1996.
• [35]Pearlin LI, Nguyen KB, Schieman S, Milkie MA: The life-course origins of mastery among older people. J Health Soc Behav 2007, 48:164-179.
• [36]Pearlin LI, Schooler C: The structure of coping. J Health Soc Behav 1978, 19:2-21.
• [37]van Eijk LM, Kempen GI, van Sonderen FL: [A short scale for measuring social support in the elderly: the SSL12-I]. Tijdschr Gerontol Geriatr 1994, 25:192-196.
• [38]Schreuders JPG, van den Willige G, Brosschot JF, Tellegen B, Graus GMH: Herziene handleiding De Utrechtse Coping Lijst: UCL. Omgaan met problemen en gebeurtenissen. Swes & Zeitlinger, Lisse; 1993.
• [39]Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, et al.: Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther 2011, 42:676-688.
• [40]Miller SD, Duncan BL, Brown J, Sparks JA, Claud DA: The outcome rating scale: a preliminary study of the reliability, validity, and feasibility of a brief visual analog measure. J Brief Ther 2003, 2:91-100.
• [41]van Tilburg TG: Verkregen en gewenste ondersteuning in het licht van eenzaamheidservaringen. Vrije Universiteit, Amsterdam; 1988.
• [42]Watson D, Clark LA, Tellegen A: Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988, 54:1063-1070.
• [43]Weissman AN: The dysfunctional attitudes scale: a validation study (Doctoral dissertation, University of Pennsylvania, 1979). Dissert Abstracts Int 1979, 40:1389B-1390B.
• [44]de Graaf LE, Roelofs J, Huibers MJ: Measuring dysfunctional attitudes in the general population: the dysfunctional attitude scale (form a) revised. Cognit Ther Res 2009, 33:345-355.
• [45]Vanheule S, DeSmet M, Rosseel Y: The factorial structure of the Dutch translation of the inventory of interpersonal problems: a test of the long and short versions. Psychol Assess 2006, 18:112-117.
• [46]van Rijsbergen GD, Bockting CL, Berking M, Koeter MW, Schene AH: Can a one-item mood scale do the trick? Predicting relapse over 5.5-years in recurrent depression. PloS One 2012, 7:e46796.
• [47]Duncan BL, Miller SD, Sparks JA, Claud DA, Reynolds LR, Brown J, et al.: The session rating scale: preliminary psychometric properties of a “working” alliance measure. J Brief Ther 2003, 3:3-12.
• [48]Horvath AO, Greenberg LS: Development and validation of the working alliance inventory. J Counsel Psychol 1989, 36:223-233.
• [49]Centraal Bureau voor Statistiek: Integrale Veiligheidsmonitor 2009 Landelijke rapportage. Centraal Bureau voor Statistiek, Den Haag; 2009.
• [50]Fenwick E, O’Brien BJ, Briggs A: Cost-effectiveness acceptability curves–facts, fallacies and frequently asked questions. Health Econ 2004, 13:405-415.
• [51]Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME: Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry 2013, 70:1152-1160.